RSV and Infants: What You Need to Know

Nov 1st, 2023 | 12:00 PM – 1:00 PM EST

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTI) in children globally, with cases of severe RSV disease occurring in infants less than 6 months of age. RSV is also the leading cause of infant hospitalizations in Canada. Due to the limited therapeutic options available to manage RSV illness, the focus has been on disease prevention. At present, there is no vaccine available to prevent RSV. Monoclonal antibodies provide temporary passive protection. Palivizumab has been in use for over 20 years in Canada to protect infants at high risk of severe disease. Nirsevimab has recently been authorized for the protection of all infants against RSV disease.

Upon completion of this program, participants will be able to:

Recognize the prevalence and burden of RSV disease in all infants
Explain the role of monoclonal antibodies for protection against preventable disease
Apply approved RSV immunoprophylaxis in clinical practice
Employ strategies to discuss RSV immunoprophylaxis for all infants and children

Can’t attend? Register to receive a notification once the webinar is available on-demand.

This webinar will feature:

form-head-title

Registration Form

First Name

Last Name

Confirm Email

Zoom Id

Moodle Course Id

Post Id

Country

Region

SCFHS Number

Profession

Primary Area of Focus

select-webinars-title

Select Which Webinars You’d Like to Attend

Webinar Custom Select *

RSV and Infants: What You Need to Know

MDBC Consent *

I consent to receive email communications from MDBriefCase and its affiliates regarding upcoming programs, events and other resources that may be of interest. Please note: This consent is required for registration and continued participation in the program.

Partner Consent

I'm also interested in receiving emailed news, information and updates from our partners, which may be of interest. You may opt out of these emails at any time.

GSK Information Consent

I consent that GSK or its affiliates may use my data for CME accreditation and SFDA disclosure purposes.

GSK Communication Consent

If you haven’t already consented to receive GSK Email or Mobile communication, tick the box to opt in. Note: Emails or SMSs may contain promotional information from GSK and its group. You can change your mind at any time and unsubscribe.

Email Notification

To make sure our emails reach your inbox, please add communications@mdbriefcase.com to your contact list.

RSV and Infants: What You Need to Know

Nov 1st, 2023 | 12:00 PM – 1:00 PM EST

Cora Constantinescu

John Yaremko

Vivien Brown

Registration Form

Select Which Webinars You’d Like to Attend

Company

Help

Legal